share_log

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $109

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $109

Canaccord Genuity维持对Ultragenyx制药的买入,将目标股价下调至109美元
Benzinga ·  05/06 13:35

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $111 to $109.

Canaccord Genuity分析师惠特尼·伊杰姆维持Ultragenyx Pharmaceutical(纳斯达克股票代码:RARE)的买入并将目标股价从111美元下调至109美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发